• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于识别有代谢功能障碍相关脂肪性肝炎风险患者的非侵入性评估

Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.

作者信息

Kalligeros Markos, Danpanichkul Pojsakorn, Noureddin Mazen

机构信息

Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas.

出版信息

Gastroenterol Hepatol (N Y). 2024 Nov;20(11):672-677.

PMID:39886331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11775999/
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease, is a major global health issue and a leading cause of chronic liver disease. The prevalence of MASLD is increasing globally, with the disease in some patients progressing to metabolic dysfunction-associated steatohepatitis (MASH), which significantly raises the risk of fibrosis, cirrhosis, and adverse outcomes. Accurate identification of patients with at-risk MASH, defined as MASH with a fibrosis stage of 2 or higher, is critical for timely intervention and management. Although liver biopsy remains the gold standard for diagnosing MASH, its invasive nature, potential complications, and variability in interpretation necessitate the implementation of noninvasive tests (NITs). NITs hold the potential for reducing reliance on liver biopsies, enhancing early diagnosis, and improving patient management of chronic liver disease. Continued research and validation are essential to optimize these tools for clinical application. This article explores current NITs, including imaging biomarkers, combined imaging and serum biomarkers, advanced biomarkers and composite scores, as well as artificial intelligence-based approaches, which also show promise in improving the accuracy of noninvasive at-risk MASH detection.

摘要

代谢功能障碍相关脂肪性肝病(MASLD),以前称为非酒精性脂肪性肝病,是一个重大的全球健康问题,也是慢性肝病的主要原因。MASLD在全球的患病率正在上升,一些患者的病情会进展为代谢功能障碍相关脂肪性肝炎(MASH),这显著增加了纤维化、肝硬化和不良后果的风险。准确识别有风险的MASH患者(定义为纤维化分期为2期或更高的MASH)对于及时干预和管理至关重要。尽管肝活检仍然是诊断MASH的金标准,但其侵入性、潜在并发症以及解读的变异性使得有必要实施非侵入性检测(NITs)。NITs有可能减少对肝活检的依赖,加强早期诊断,并改善慢性肝病患者的管理。持续的研究和验证对于优化这些工具用于临床应用至关重要。本文探讨了当前的NITs,包括成像生物标志物、成像与血清生物标志物联合检测、先进生物标志物和综合评分,以及基于人工智能的方法,这些方法在提高无创性有风险MASH检测的准确性方面也显示出前景。

相似文献

1
Noninvasive Assessment to Identify Patients With At-Risk Metabolic Dysfunction-Associated Steatohepatitis.用于识别有代谢功能障碍相关脂肪性肝炎风险患者的非侵入性评估
Gastroenterol Hepatol (N Y). 2024 Nov;20(11):672-677.
2
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢相关脂肪性肝病中肝纤维化和疾病严重程度的无创性评估检测。
Semin Liver Dis. 2024 Aug;44(3):287-299. doi: 10.1055/s-0044-1788277. Epub 2024 Jul 9.
3
Noninvasive identification of metabolic dysfunction-associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study.代谢功能障碍相关脂肪性肝炎的非侵入性识别(INFORM MASH):一项回顾性队列和疾病建模研究。
Expert Rev Gastroenterol Hepatol. 2025 Apr;19(4):427-435. doi: 10.1080/17474124.2025.2477249. Epub 2025 Mar 21.
4
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.基于肝活检的验证、确认和比较新型及传统非酒精性脂肪性肝病无创性诊断指标的诊断效能:一项多中心大样本研究。
Metabolism. 2023 Oct;147:155666. doi: 10.1016/j.metabol.2023.155666. Epub 2023 Jul 30.
5
Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database.了解MASH:TARGET-NASH数据库中按疾病严重程度对进展和临床结果的考察。
Adv Ther. 2025 Feb;42(2):1165-1195. doi: 10.1007/s12325-024-03085-4. Epub 2024 Dec 30.
6
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.一步法无创诊断高危人群代谢相关脂肪性肝炎及纤维化。
United European Gastroenterol J. 2024 Sep;12(7):919-929. doi: 10.1002/ueg2.12589. Epub 2024 Aug 4.
7
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.年龄对NIS2+™及其他用于评估肝病和检测高危代谢相关脂肪性肝病(MASH)的非侵入性血液检测的影响
JHEP Rep. 2024 Jan 19;6(4):101011. doi: 10.1016/j.jhepr.2024.101011. eCollection 2024 Apr.
8
Noninvasive tests and diagnostic pathways to MASH diagnosis in the United States: a retrospective observational study.美国非侵入性检测与MASH诊断的诊断途径:一项回顾性观察研究
J Med Econ. 2025 Dec;28(1):314-322. doi: 10.1080/13696998.2025.2468582. Epub 2025 Feb 28.
9
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南:代谢功能障碍相关脂肪性肝病(MASLD)的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
10
Hepatocellular carcinoma risk prediction and early detection in patients with metabolic dysfunction associated steatotic liver disease.代谢功能障碍相关脂肪性肝病患者肝细胞癌的风险预测与早期检测
Transl Gastroenterol Hepatol. 2024 Oct 12;9:67. doi: 10.21037/tgh-24-41. eCollection 2024.

本文引用的文献

1
Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.MAST、FAST 和 MEFIB 预测代谢相关脂肪性肝炎的性能。
J Gastroenterol Hepatol. 2024 Aug;39(8):1656-1662. doi: 10.1111/jgh.16589. Epub 2024 Apr 30.
2
Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.前瞻性头对头比较非侵入性评分对 2 型糖尿病患者纤维化 MASH 的诊断价值。
J Hepatol. 2024 Aug;81(2):195-206. doi: 10.1016/j.jhep.2024.03.023. Epub 2024 Mar 27.
3
AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.美国肝病研究学会关于基于血液的肝纤维化和脂肪变性非侵入性肝病评估的实践指南。
Hepatology. 2025 Jan 1;81(1):321-357. doi: 10.1097/HEP.0000000000000845. Epub 2024 Mar 15.
4
AASLD Practice Guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis.美国肝病研究学会关于基于成像的肝纤维化和脂肪变性非侵入性肝病评估的实践指南。
Hepatology. 2025 Feb 1;81(2):672-724. doi: 10.1097/HEP.0000000000000843. Epub 2024 Mar 15.
5
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
6
NIS2+ as a screening tool to optimize patient selection in metabolic dysfunction-associated steatohepatitis clinical trials.NIS2+ 作为一种筛选工具,可优化代谢功能障碍相关脂肪性肝炎临床试验中的患者选择。
J Hepatol. 2024 Feb;80(2):209-219. doi: 10.1016/j.jhep.2023.10.038. Epub 2023 Dec 5.
7
Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020.美国脂肪性肝病(MASLD、MetALD 和 ALD)的流行情况:NHANES 2017-2020。
Clin Gastroenterol Hepatol. 2024 Jun;22(6):1330-1332.e4. doi: 10.1016/j.cgh.2023.11.003. Epub 2023 Nov 8.
8
Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.开发和验证一种图像生物标志物,以识别与代谢功能障碍相关的脂肪性肝炎:MR-MASH 评分。
Liver Int. 2024 Jan;44(1):202-213. doi: 10.1111/liv.15766. Epub 2023 Oct 30.
9
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).血清鉴定高危 MASH:代谢组学-先进的脂肪性肝炎纤维化评分(MASEF)。
Hepatology. 2024 Jan 1;79(1):135-148. doi: 10.1097/HEP.0000000000000542. Epub 2023 Jul 24.
10
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.